Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Lilly's Combo Treatment Improves OS in Gastric Cancer Patients

September 18, 2014 3:58 pm | News | Comments

Eli Lilly and Co. announced that results of the global Phase 3 trial of ramucirumab (Cyramza) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in a sholarly journal. Read more...

Otsuka, NuView Life Sciences Enter Global Licensing Agreement

September 18, 2014 3:50 pm | News | Comments

NuView Life Sciences announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co. to further develop and commercialize NuView's investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. Read more...

FDA OKs Faster-Acting Label for ED Drug Stendra

September 18, 2014 3:43 pm | News | Comments

Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated. Read more...                       

Advertisement

Texas A&M to Dedicate Key Element of Vaccine Center

September 18, 2014 3:28 pm | News | Comments

Texas Gov. Rick Perry will join other dignitaries in College Station at the dedication of what's described as a national pandemic influenza vaccine facility. Read more...                       

Cubist Opening New International Headquarters in Zurich

September 18, 2014 9:21 am | News | Comments

Cubist Pharmaceuticals Inc. announced the official opening of its international headquarters in Zurich, Switzerland, reinforcing its commitment to global public health. Read more...                    

Ryzodeg Offers Glycemic Control With Fewer Injections

September 18, 2014 9:17 am | News | Comments

Data presented by Novo Nordisk show that Ryzodeg (insulin degludec/insulin aspart), administered twice daily, provides successful glycemic control with fewer injections than a basal-bolus regimen. Read more...            

BI, CureVac Collaborate on Next-Gen Lung Cancer Immunotherapy

September 18, 2014 9:09 am | News | Comments

Boehringer Ingelheim and CureVac jointly announced an exclusive global license and development collaboration focusing on CureVac’s CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer. Read more...

UK Nurse Will Give Blood to Treat U.S. Ebola Patient

September 18, 2014 9:01 am | by Maria Cheng, AP Medical Writer | News | Comments

A British nurse who survived Ebola has traveled to the United States to donate blood to an American still battling the disease, an experimental measure some scientists think can help patients fight off the virus. Read more...       

Advertisement

Bayer to Split Off Polymer Division

September 18, 2014 7:40 am | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The move is part of an effort to focus the group on its health care and crop science businesses. Read more...     

Gilead Releases Phase 2 Pancreatic Cancer Data

September 17, 2014 3:28 pm | News | Comments

Gilead Sciences Inc. announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. Read more...

Covance, Frenova Renal Research Collaborate on Kidney, Renal Diseases

September 17, 2014 3:24 pm | News | Comments

Covance Inc. and Frenova Renal Research announced a new research collaboration designed to find more effective treatments for patients living with chronic kidney disease (CKD) and end stage renal disease (ESRD). Read more...        

Lilly Sells Failed Oncology Drug to Denovo Biopharma

September 17, 2014 3:18 pm | News | Comments

Denovo Biopharma LLC announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Co. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally. Read more...           

Sun Pharma Licenses Merck Psoriasis Drug for $80M

September 17, 2014 3:02 pm | News | Comments

Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday. Sun will pay Merck $80 million upfront and will gain the right to market the drug, called tildrakizumab. Read more...    

Advertisement

1st Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:46 pm | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Read more...                       

Sanofi Enters Groundbreaking Heart Disease Collaboration with MyoKardia

September 17, 2014 10:57 am | News | Comments

Sanofi and MyoKardia Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. Read more...   

EMD Serono, Sutro Biopharma Partner on ADCs

September 17, 2014 10:52 am | News | Comments

EMD Serono Inc., a subsidiary of Merck KGaA, and Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). Read more...

Merck Diabetes Drug Hits Endpoints in Japanese Study

September 17, 2014 10:44 am | News | Comments

Merck announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. Read more...         

Glenmark's TRPA1 Antagonist Excels in Phase 2a

September 17, 2014 10:33 am | News | Comments

Glenmark Pharmaceuticals announced that its first-in-class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536, has shown positive data in a Phase 2a study conducted on 138 patients in Europe and India. Read more...       

Auxilium Adopts 'Poison Pill' Plan After $1.41B Offer from Endo

September 17, 2014 10:21 am | News | Comments

The board of Auxilium Pharmaceuticals Inc. has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker. Read more...

Relmada in MOA Agreement With MSKCC

September 16, 2014 3:47 pm | News | Comments

Relmada Therapeutics Inc. announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER. Read more...         

TapImmune Releases Interim Data on Phase 1 Cancer Trial

September 16, 2014 3:39 pm | News | Comments

TapImmune Inc. reported that analysis of the interim data from the first 13 patients in a Phase 1 clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of five naturally processed folate receptor alpha Class II antigenic epitopes. Read more...

Amarin Committed to Completing Cardiovascular Outcomes Study

September 16, 2014 3:34 pm | News | Comments

Amarin Corp. announced its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) cardiovascular outcomes study. Read more...                 

Mylan to Begin Phase 3 Trials on Key Generics

September 16, 2014 3:28 pm | News | Comments

Mylan Inc. announced it is initiating Phase 3 clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus.  Read more...                   

Nektar Says FDA Clears Constipation Drug Movantik

September 16, 2014 2:41 pm | News | Comments

Nektar Therapeutics said Tuesday that U.S. regulators approved its drug Movantik, a once-per-day treatment for constipation caused by opioid painkillers. Movantik, or naloxegol, is approved for adults who have chronic pain that is not caused by cancer. Read more...

Lilly, AstraZeneca Team Up on Alzheimer's Drug

September 16, 2014 11:43 am | News | Comments

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing. Read more...      

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading